The FDA granted 510(k) clearance and a CLIA waiver to Diasorin’s Liaison Nes rapid molecular group A strep test, giving clinicians a faster point-of-care option for acute pharyngitis. Diasorin said the assay delivers results in about 15 minutes with under one minute of hands-on time. Diasorin’s platform attributes include room-temperature reagent storage and a compact, cloud-connected device for real-time reporting in outpatient and decentralized settings. The new test is the second cleared assay on the Nes menu, after the company previously received clearance and CLIA waiver for a respiratory panel covering influenza A/B, RSV and COVID-19. Diasorin also tied the regulatory milestone to commercial targets outlined at an investor day, where executives projected Nes revenue exceeding $150 million by 2030, with a separate Liaison Plex gastrointestinal panel also cleared in May.